No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
GNPX Genprex
- 2.0800
- -0.1300-5.88%
Close Jun 18 16:00 ET
- 2.1300
- +0.0500+2.40%
Post 19:13 ET
4.36MMarket Cap-110P/E (TTM)
2.2600High2.0100Low24.15KVolume2.2600Open2.2100Pre Close52.47KTurnover1.16%Turnover RatioLossP/E (Static)2.10MShares42.000052wk High0.50P/B4.33MFloat Cap2.010052wk Low--Dividend TTM2.08MShs Float778.0000Historical High--Div YieldTTM11.31%Amplitude2.0100Historical Low2.1730Avg Price1Lot Size
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
12 Health Care Stocks Moving In Friday's Intraday Session
GainersNovo Integrated Sciences (NASDAQ:NVOS) shares rose 120.0% to $0.99 during Friday's regular session. The company's market cap stands at $18.9 million. Anebulo Pharmaceuticals (NASDAQ:ANEB) share
Genprex to Present at the 2024 BIO International Convention
Presentation to Highlight the Company's Gene Therapies for Cancer and Diabetes AUSTIN, Texas — (May 30, 2024) — Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical
Genprex | 10-Q: Quarterly report
Express News | HC Wainwright & Co. Reiterates Buy on Genprex, Maintains $10 Price Target
Genprex Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/15/2024 316.67% HC Wainwright & Co. → $10 Reiterates Buy → Buy 04/04/2024 316.67% HC Wainwright & Co. →
Genprex's Promising Clinical Trials and Leadership Drive Buy Rating
Comments
$Genprex(GNPX.US$
NEWS
Genprex Doses First Patient in Acclaim-3 Clinical Study of Reqorsa® Immunogene Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer
Genprex announced the first patient dosing in its Phase 1 Acclaim-3 clinical study of Reqorsa Immunogene Therapy in combination with Tecentriq to treat extensive-stage small cell lung cancer (ES-SCLC). This trial, which aims to determine the maximum tolerated dose for a Phase 2 expansion expected in the second half of 2024, ...
NEWS
Genprex Doses First Patient in Acclaim-3 Clinical Study of Reqorsa® Immunogene Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer
Genprex announced the first patient dosing in its Phase 1 Acclaim-3 clinical study of Reqorsa Immunogene Therapy in combination with Tecentriq to treat extensive-stage small cell lung cancer (ES-SCLC). This trial, which aims to determine the maximum tolerated dose for a Phase 2 expansion expected in the second half of 2024, ...
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg